Session

IBD (Posters)

DE NOVO INFLAMMATORY BOWEL DISEASE PICKED UP VIA NATIONAL BOWEL CANCER SCREENING PROGRAMME: 10 YEAR EXPERIENCE AT A LARGE ENGLISH SCREENING CENTRE
DE NOVO INFLAMMATORY BOWEL DISEASE PICKED UP VIA NATIONAL BOWEL CANCER SCREENING PROGRAMME: 10 YEAR EXPERIENCE AT A LARGE ENGLISH SCREENING CENTRE

IBD (Posters)  et al.

BIOLOGICALS AND SMALL MOLECULE COMBOTHERAPIES:PROMISING EXPERIENCE IN REFRACTORY IBD PATIENTS
BIOLOGICALS AND SMALL MOLECULE COMBOTHERAPIES:PROMISING EXPERIENCE IN REFRACTORY IBD PATIENTS

IBD (Posters)  et al.

POSSIBILITIES FOR DIFFERENTIAL DIAGNOSIS OF NOSOLOGICAL FORMS OF INFLAMMATORY BOWEL DISEASE USING ERYTHROCYTE AND BLOOD SERUM MEMBRANE FATTY ACIDS
POSSIBILITIES FOR DIFFERENTIAL DIAGNOSIS OF NOSOLOGICAL FORMS OF INFLAMMATORY BOWEL DISEASE USING ERYTHROCYTE AND BLOOD SERUM MEMBRANE FATTY ACIDS

IBD (Posters)  et al.

DISEASE ACTIVITY PATTERNS OF INFLAMMATORY BOWEL DISEASE - A DANISH NATIONWIDE COHORT STUDY 1995-2018
DISEASE ACTIVITY PATTERNS OF INFLAMMATORY BOWEL DISEASE - A DANISH NATIONWIDE COHORT STUDY 1995-2018

IBD (Posters)  et al.

DELAYED IBD DIAGNOSIS LEADS TO WORSE OUTCOMES OVER YEARS, WITH MULTIPLE IMPLICATIONS ON SERVICE DELIVERY
DELAYED IBD DIAGNOSIS LEADS TO WORSE OUTCOMES OVER YEARS, WITH MULTIPLE IMPLICATIONS ON SERVICE DELIVERY

IBD (Posters)  et al.

DELAYED IBD DIAGNOSIS INCREASES RISK OF REQUIRING BIOLOGICS IN FIRST 4-YEARS - AN INCEPTION COHORT STUDY
DELAYED IBD DIAGNOSIS INCREASES RISK OF REQUIRING BIOLOGICS IN FIRST 4-YEARS - AN INCEPTION COHORT STUDY

IBD (Posters)  et al.

THE BURDEN OF URINARY SYMPTOMS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A CROSS-SECTIONAL OBSERVATIONAL STUDY
THE BURDEN OF URINARY SYMPTOMS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A CROSS-SECTIONAL OBSERVATIONAL STUDY

IBD (Posters)  et al.

SYSTEMATIC REVIEW AND META-ANALYSIS: MICROSCOPIC COLITIS IS A RISK FACTOR FOR LOW BONE DENSITY
SYSTEMATIC REVIEW AND META-ANALYSIS: MICROSCOPIC COLITIS IS A RISK FACTOR FOR LOW BONE DENSITY

IBD (Posters)  et al.

NON-INVASIVE ASSESSMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
NON-INVASIVE ASSESSMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

IBD (Posters)  et al.

TRYPTOPHAN DEGRADATION PRODUCTS AS UNIFYING BIOMARKERS OF SEVERITY AND LONG-TERM DISEASE CONTROL IN CHRONIC INFLAMMATORY DISEASES
TRYPTOPHAN DEGRADATION PRODUCTS AS UNIFYING BIOMARKERS OF SEVERITY AND LONG-TERM DISEASE CONTROL IN CHRONIC INFLAMMATORY DISEASES

IBD (Posters)  et al.

6-THIOGUANINE NUCLEOTIDE LEVELS AND ANTI-TUMOUR NECROSIS FACTOR ALPHA TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE PATIENTS ON COMBINATION THERAPY: A RETROSPECTIVE MULTICENTRE STUDY
6-THIOGUANINE NUCLEOTIDE LEVELS AND ANTI-TUMOUR NECROSIS FACTOR ALPHA TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE PATIENTS ON COMBINATION THERAPY: A RETROSPECTIVE MULTICENTRE STUDY

IBD (Posters)  et al.

HUMAN INTESTINAL CD103+SIRP-ALPHA+ CONVENTIONAL DENDRITIC CELLS FROM PATIENTS WITH CROHN´S DISEASE PRIME IL-17+ T-CELLS
HUMAN INTESTINAL CD103+SIRP-ALPHA+ CONVENTIONAL DENDRITIC CELLS FROM PATIENTS WITH CROHN´S DISEASE PRIME IL-17+ T-CELLS

IBD (Posters)  et al.

INCREASE IN CIRCULATING T AND B LYMPHOCYTE SUBSETS AFTER TREATMENT WITH THE POTENT, SELECTIVE, ORAL, SMALL MOLECULE ALPHA4BETA-7 INHIBITOR MORF-057 IN HEALTHY SUBJECTS
INCREASE IN CIRCULATING T AND B LYMPHOCYTE SUBSETS AFTER TREATMENT WITH THE POTENT, SELECTIVE, ORAL, SMALL MOLECULE ALPHA4BETA-7 INHIBITOR MORF-057 IN HEALTHY SUBJECTS

IBD (Posters)  et al.

LOW FREQUENCIES OF CIRCULATING INHIBITORY TIGIT+CD38+ EFFECTOR T CELLS IDENTIFY AN IMMUNOLOGICALLY DISTINCT SUBGROUP OF PEDIATRIC PATIENTS WITH SEVERE CROHN’S DISEASE
LOW FREQUENCIES OF CIRCULATING INHIBITORY TIGIT+CD38+ EFFECTOR T CELLS IDENTIFY AN IMMUNOLOGICALLY DISTINCT SUBGROUP OF PEDIATRIC PATIENTS WITH SEVERE CROHN’S DISEASE

IBD (Posters)  et al.

INFLUENCE OF DIABETES MELLITUS ON INFLAMMATORY BOWEL DISEASE COURSE AND TREATMENT OUTCOMES.A SYSTEMATIC REVIEW WITH META-ANALYSIS
INFLUENCE OF DIABETES MELLITUS ON INFLAMMATORY BOWEL DISEASE COURSE AND TREATMENT OUTCOMES.A SYSTEMATIC REVIEW WITH META-ANALYSIS

IBD (Posters)  et al.

ENDOSCOPIC SCORES AS PREDICTORS OF TREATMENT FAILURE IN ULCERATIVE COLITIS
ENDOSCOPIC SCORES AS PREDICTORS OF TREATMENT FAILURE IN ULCERATIVE COLITIS

IBD (Posters)  et al.

EXPLORATORY ANALYSIS OF FILGOTINIB SAFETY DATA IN A SELECTED POPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM FINCH 1–4 AND DARWIN 1–3 STUDIES IN PERSPECTIVE TO INTEGRATED ULCERATIVE COLITIS SAFETY DATA
EXPLORATORY ANALYSIS OF FILGOTINIB SAFETY DATA IN A SELECTED POPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM FINCH 1–4 AND DARWIN 1–3 STUDIES IN PERSPECTIVE TO INTEGRATED ULCERATIVE COLITIS SAFETY DATA

IBD (Posters)  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY
EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY

IBD (Posters)  et al.

DEFINITIVE SURGICAL MANAGEMENT OF PERIANAL FISTULAS IN ADULTS WITH CROHN’S DISEASE: A CROSS-SECTIONAL ANALYSIS OF LOCAL PRACTICE IN AUSTRALIA AND NEW ZEALAND
DEFINITIVE SURGICAL MANAGEMENT OF PERIANAL FISTULAS IN ADULTS WITH CROHN’S DISEASE: A CROSS-SECTIONAL ANALYSIS OF LOCAL PRACTICE IN AUSTRALIA AND NEW ZEALAND

IBD (Posters)  et al.

ANTI-INFLAMMATORY AND BARRIER STABILIZING EFFECTS OF A HERBAL COMBINATION MEDICINE OF MYRRH, COFFEE CHARCOAL AND CHAMOMILE FLOWER EXTRACT IN A MULTI-COMPONENT CELL MODEL OF THE INFLAMED INTESTINAL MUCOSA
ANTI-INFLAMMATORY AND BARRIER STABILIZING EFFECTS OF A HERBAL COMBINATION MEDICINE OF MYRRH, COFFEE CHARCOAL AND CHAMOMILE FLOWER EXTRACT IN A MULTI-COMPONENT CELL MODEL OF THE INFLAMED INTESTINAL MUCOSA

IBD (Posters)  et al.

Item 381 - 400 / 612
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
20
21 22 23 24 25 26 27 28 29 30 31